首页> Clinical cancer research : an official journal of the American Association for Cancer Research> Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma.

Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma.

导出 OA

翻译打印收藏纠错

第一作者： Johanna,Bendell

第一单位： Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee. jbendell@tnonc.com.

作者： Johanna,Bendell ^[1] ; Valerie,Andre ^[2] ; Alan,Ho ^[3] ; Ragini,Kudchadkar ^[4] ; Michael,Migden ^[5] ; Jeffrey,Infante ^[6] ; Ramon V,Tiu ^[7] ; Celine,Pitou ^[2] ; Trevor,Tucker ^[8] ; Les,Brail ^[9] ; Daniel,Von Hoff ^[10]

作者单位： Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee. jbendell@tnonc.com. ^[1] Eli Lilly and Company, Erl Wood, United Kingdom. ^[2] Memorial Sloan Kettering Cancer Center, New York, New York. ^[3] Emory Winship Cancer Institute, Atlanta, Atlanta, GA. ^[4] University of Texas, MD Anderson Cancer Center, Houston, Texas. ^[5] Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee. ^[6] Eli Lilly and Company, Indianapolis, Indiana. ^[7] Ignyta, Inc., San Diego, California. ^[8] Infinity Pharmaceuticals, Cambridge, Massachusetts. ^[9] Translational Genomics Research Institute, Phoenix, Arizona.;Honorhealth Research Institute, Scottsdale, Arizona. ^[10]